Accuray Incorporated: stock overview
Price
$2.80
November 13, 2026
What Ploutos Investor adds for Accuray
Part of Ploutos Investor, €9.99 a month
- The full history: 17 fiscal years, from FY2010
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 36% since Nov 6, 2026, when the 10-Q these figures come from was filed ($4.40 then, $2.80 on Nov 13, 2026). The figures date from before that move.10-Q
- The share price was recently adjusted for a split or a spin-off that the company's last filing does not include yet. Market value, P/E, yields and the other figures measured against the price would mix the new shares with the old figures, so we leave them out until the next filing.
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
In short
Accuray had revenue of $395M over the last 12 months and a net loss of $17M. Revenue grew by 0.3% a year on average over the last 5 years. It pays no dividend.
From its SEC filings (latest fiscal year to June 30, 2026) and the price of November 13, 2026.
Its SEC filings- Market cap
- –
- 119M shares
- P/E
- –
- Revenue, 12 months
- $395M
- +0.3% a year over 5 years
- Net margin
- -4.4%
- FY2025: -0.4%, above 45% of its industry
Worth knowing
What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.
3 fiscal years in figures
Each fiscal year's figures as the company filed them, and the share price at its end.
-5.1% a year over 2 years
Fiscal years in figures
ARAY's revenue, profit, cash flow and dividend with each year-end price, from FY2010 to FY2023, 14 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Key figures
The company's current figures in five groups. Each term is explained behind its ⓘ.
Valuation
Sorry, we do not have enough data
for the “Valuation” group
Profitability
- Gross margin
- 28.0%
- Operating margin
- -13.1%
- Net margin 3-year median: -3.5%
- -4.4%
- ROIC
- -22.1%
- ROIC, 5-year average
- -0.9%
- ROE
- -34.5%
Growth
- Revenue, yearly change
- -12.3%
- EPS, yearly change
- –
- FCF, yearly change
- –
- Revenue, average a year
- +0.3%
The yearly change compares FY2026 with FY2025.
Balance sheet
- Cash
- $42M
- Total debt
- –
- Net cash
- –
- Net debt / EBITDA
- –
- Interest cover
- -1.5x
- Current ratio
- 1.56
Balance sheet of September 30, 2026.
Returns to shareholders
- Dividend yield
- 0.00%
- Buybacks
- –
- Total returned
- 0.00%
- Shares, yearly change
- +6.0%
Against its industry
Where its margins and returns stood in fiscal 2025 among the SEC filers of its industry (SIC code 38).
Gross margin
32.1%
Above 13% of the 161 companies in its industry, and 42% of all.
Operating margin
1.7%
Above 49% of the 186 companies in its industry, and 39% of all.
Net margin
-0.4%
Above 45% of the 189 companies in its industry, and 32% of all.
ROE
-3.0%
Above 39% of the 174 companies in its industry, and 26% of all.
ROA
-0.4%
Above 44% of the 190 companies in its industry, and 31% of all.
Revenue growth
2.7%
Above 31% of the 186 companies in its industry, and 37% of all.
From the yearly figures every company files with the SEC, for those with revenue of at least $25 million. The industry is the first two digits of the SIC code.
The company at the SEC
How it is registered and when its fiscal year ends.
- Name at the SEC
- ACCURAY INC
- CIK
- 1138723
- Exchange
- NASDAQ
- Industry (SIC)
- 3841 · Surgical & Medical Instruments & Apparatus
- Fiscal year ends
- June 30
- Latest annual report
- June 30, 2026
- Reporting currency
- USD
- Shares
- 119M
Other companies: Healthcare
The largest companies of the same sector, each with its own page.
- LLYEli Lilly and Company+0,00%Compare with ARAY
- JNJJohnson & Johnson+0,00%Compare with ARAY
- ABBVAbbVie+0,00%Compare with ARAY
- UNHUnitedHealth+0,00%Compare with ARAY
- MRKMerck & Company+0,00%Compare with ARAY
- AMGNAmgen+0,00%Compare with ARAY
- TMOThermo Fisher Scientific+0,00%Compare with ARAY
- ABTAbbott Laboratories+0,00%Compare with ARAY
The full analysis
What do Accuray's filings show?
These are Accuray's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue does ARAY have?
Accuray had revenue of $395M over the last 12 months. Over the last 5 years it changed by +0.3% a year on average.
Does ARAY pay a dividend?
No. Accuray paid no regular dividend over the last 12 months.
Where do the figures come from?
From Accuray Incorporated's SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.